IO Biotech, Inc. - Common Stock, par value $0.001 per share (IOBTQ)
CUSIP: 449778109
Q4 2024 13F Holders as of 31 Dec 2024
- Type / Class
- Equity / Common Stock, par value $0.001 per share
- Shares outstanding
- 73,755,848
- Total 13F shares
- 19,692,862
- Share change
- -4,662,796
- Total reported value
- $18,114,763
- Price per share
- $0.92
- Number of holders
- 26
- Value change
- -$4,833,042
- Number of buys
- 10
- Number of sells
- 9
Quarterly Holders Quick Answers
What is CUSIP 449778109?
CUSIP 449778109 identifies IOBTQ - IO Biotech, Inc. - Common Stock, par value $0.001 per share in SEC institutional holdings data.
Need full ownership history?
Open the full security ownership history page.
Next holder-history checks
These links keep the next click tied to holder verification, nearby quarters, or outside-13F ownership context.
- Back to full security ownership history for the broader multi-quarter picture.
- Latest 13F filings for newly reported positions across managers.
- Latest Schedule 13D/13G reports for ownership changes outside the 13F cadence.
- SEC investors directory for manager drilldown.
Explore More Reporting Periods
Jump to adjacent filing periods for faster comparison and easier crawl discovery.
Recent filing periods for CUSIP 449778109:
Top shareholders of IOBTQ - IO Biotech, Inc. - Common Stock, par value $0.001 per share (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Ownership % is shown only when it is directly reported or safely comparable across share classes.
Methodology: rows are grouped by holder and ranked by the holder's primary source value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
| Holder | Source | Role / Reporting | Ownership % | Shares | Holdings Value | 12M Net Δ | As of | Details |
|---|---|---|---|---|---|---|---|---|
| Invest A/s Lundbeckfond |
3/4/5
|
Director, 10%+ Owner |
—
mixed-class rows
|
21,851,920
mixed-class rows
|
$14,438,960 | — | 09 Aug 2023 | |
| Vivo Capital IX, LLC |
3/4/5
|
10%+ Owner |
—
mixed-class rows
|
12,346,878
mixed-class rows
|
$9,510,598 | — | 09 Aug 2023 | |
| Vivo Capital, LLC |
13F
|
Company |
8.4%
|
6,173,439
|
$6,482,111 | — | 30 Sep 2024 | |
| Novo Holdings A/S |
3/4/5
13F
|
10%+ Owner · Company |
4.5%
from 13F
|
6,823,584
mixed-class rows
|
$5,709,989 | — | 25 Jul 2024 | |
| Samsara BioCapital, LLC |
13F
|
Company |
4.9%
|
3,640,015
|
$3,822,016 | — | 30 Sep 2024 | |
| HBM Healthcare Investments (Cayman) Ltd. |
3/4/5
|
10%+ Owner |
—
class O/S missing
|
2,690,545
|
$2,784,714 | — | 09 Nov 2021 | |
| Samsara BioCapital, L.P. |
13D/G
|
— |
3.8%
|
2,631,578
|
$2,578,946 | $0 | 31 Dec 2024 | |
| PFM Health Sciences, LP |
13F
|
Company |
3.2%
|
2,341,107
|
$2,458,163 | — | 30 Sep 2024 | |
| MORGAN STANLEY |
13F
|
Company |
3%
|
2,202,085
|
$2,312,189 | — | 30 Sep 2024 | |
| MARSHALL WACE, LLP |
13F
|
Company |
2.9%
|
2,105,262
|
$2,210,526 | — | 30 Sep 2024 | |
| Claus A. Andersson |
3/4/5
|
Director |
—
class O/S missing
|
1,791,490
|
$1,854,192 | — | 09 Nov 2021 | |
| BANK OF AMERICA CORP /DE/ |
13F
|
Company |
2.2%
|
1,651,515
|
$1,734,091 | — | 30 Sep 2024 | |
| Pivotal bioVenture Partners Investment Advisor LLC |
13F
|
Company |
1.2%
|
864,197
|
$907,407 | — | 30 Sep 2024 | |
| Kurma Partners |
3/4/5
|
10%+ Owner |
—
class O/S missing
|
623,428
|
$645,248 | — | 09 Aug 2023 | |
| Logos Global Management LP |
13F
|
Company |
0.67%
|
493,827
|
$518,518 | — | 30 Sep 2024 | |
| Vanessa Malier |
3/4/5
|
Director |
—
class O/S missing
|
430,477
|
$445,544 | — | 09 Nov 2021 | |
| BRIDGEWAY CAPITAL MANAGEMENT, LLC |
13F
|
Company |
0.27%
|
199,623
|
$209,604 | — | 30 Sep 2024 | |
| Soleus Capital Management, L.P. |
13F
|
Company |
0.26%
|
192,670
|
$202,304 | — | 30 Sep 2024 | |
| UBS Group AG |
13F
|
Company |
0.15%
|
107,906
|
$113,301 | — | 30 Sep 2024 | |
| RENAISSANCE TECHNOLOGIES LLC |
13F
|
Company |
0.13%
|
97,000
|
$101,850 | — | 30 Sep 2024 | |
| ACADIAN ASSET MANAGEMENT LLC |
13F
|
Company |
0.08%
|
60,650
|
$63,000 | — | 30 Sep 2024 | |
| Marex Group plc |
13F
|
Company |
0.06%
|
45,000
|
$47,250 | — | 30 Sep 2024 | |
| GEODE CAPITAL MANAGEMENT, LLC |
13F
|
Company |
0.05%
|
33,307
|
$34,972 | — | 30 Sep 2024 | |
| TWO SIGMA INVESTMENTS, LP |
13F
|
Company |
0.04%
|
30,000
|
$31,500 | — | 30 Sep 2024 | |
| HRT FINANCIAL LP |
13F
|
Company |
0.04%
|
26,646
|
$27,000 | — | 30 Sep 2024 | |
| Virtu Financial LLC |
13F
|
Company |
0.02%
|
17,954
|
$19,000 | — | 30 Sep 2024 | |
| OSAIC HOLDINGS, INC. |
13F
|
Company |
0%
|
230
|
$242 | — | 30 Sep 2024 | |
| Eva Ehrnrooth |
3/4/5
|
Chief Medical Officer |
—
class O/S missing
|
120,000
|
— | — | 20 Mar 2023 | |
| Muhammad Al-Hajj |
3/4/5
|
Chief Scientific Officer |
—
class O/S missing
|
120,000
|
— | — | 20 Mar 2023 | |
| Keith A. Vendola |
3/4/5
|
Chief Financial Officer |
—
class O/S missing
|
69,469
|
— | — | 04 Nov 2021 | |
| Jack Nielsen |
3/4/5
|
Director |
—
class O/S missing
|
41,533
|
— | — | 08 Jun 2023 |
Institutional Holders of IO Biotech, Inc. - Common Stock, par value $0.001 per share (IOBTQ) as of Q4 2024
As of 31 Dec 2024,
IO Biotech, Inc. - Common Stock, par value $0.001 per share (IOBTQ) was held by
26 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
19,692,862 shares.
The largest 10 holders included
Vivo Capital, LLC, Novo Holdings A/S, PFM Health Sciences, LP, MARSHALL WACE, LLP, BANK OF AMERICA CORP /DE/, Pivotal bioVenture Partners Investment Advisor LLC, MORGAN STANLEY, Dauntless Investment Group, LLC, LANDSCAPE CAPITAL MANAGEMENT, L.L.C., and CITADEL ADVISORS LLC.
This page lists
27
institutional shareholders reporting positions in this security
for the Q4 2024 filing period.
| Investor | Option | Weight % | Change % | Value $ | * Price | Shares | Share Change | Activity | Report Period |
|---|
Compare Q4 2024 vs Q3 2024 Across Filers
Q3 2024 holders
19
Q4 2024 holders
26
Holder diff
7
| Investor | Q3 2024 Shares | Q4 2024 Shares | Share Diff | Share Chg % | Q3 2024 Value $ | Q4 2024 Value $ | Value Diff $ | Value Chg % |
|---|
Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).
Quarterly Holders Trend
Quarterly Value Trend
Quarterly Shares Trend
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.
An asterisk sign (*) next to the price indicates that the price is likely invalid.